Buy O-DSMT Powder for Advanced Laboratory Research in the USA and Europe

O-DSMT powder (O-Desmethyltramadol, systematically designated as (±)-3-methoxy-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol; also known as desmethyltramadol, O-desmethyltramadol, M1 metabolite of tramadol; CAS Registry Number: 13548-38-4 for the freebase, 13548-39-5 for the hydrochloride salt) represents a critical analytical reference standard within the synthetic opioid analgesic class, serving indispensable roles in forensic toxicology, mu-opioid receptor pharmacology, and mass spectral library development for European and USA laboratory environments. As the primary active metabolite of tramadol and a potent mu-opioid receptor agonist with significantly higher affinity than the parent compound, this compound is essential for novel psychoactive substance (NPS) monitoring, opioid screening, therapeutic drug monitoring, and confirmatory toxicological analysis. Roid Chem Store stands as the definitive USA AND European source for this rigorously characterised compound, supplying analytical-grade O-DSMT powder with 99% purity to research institutions, CROs, and pharmaceutical R&D facilities committed to reproducible, publishable outcomes. Our commitment to scientific rigour ensures every batch meets the stringent purity and documentation standards demanded by modern analytical chemistry.

Important Clarification: The abbreviation “O-DSMT” is commonly used in research chemical markets to refer to O-Desmethyltramadol (the active tramadol metabolite), NOT desmethylselegiline (which is typically abbreviated as DMS or N-desmethylselegiline). Desmethylselegiline is an MAO-B inhibitor metabolite of selegiline used in Parkinson’s disease research, whereas O-DSMT (O-Desmethyltramadol) is a mu-opioid receptor agonist and tramadol metabolite. This product page refers to O-Desmethyltramadol, the opioid analgesic research chemical. 1103

Uncompromising Purity and Analytical Characterisation

Every batch of O-DSMT Powder supplied by Roid Chem Store is guaranteed to exhibit a minimum purity of 99% (as O-Desmethyltramadol hydrochloride), as verified through comprehensive orthogonal analytical methodologies including high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR) spectroscopy, and liquid chromatography-high-resolution mass spectrometry (LC-MS/MS). This multi-technique validation approach ensures not only accurate quantification of the principal analyte but also definitive structural confirmation, distinguishing O-DSMT from related opioids such as tramadol, codeine, morphine, hydrocodone, oxycodone, and other O-desmethyl or N-desmethyl metabolites.

Each shipment is accompanied by a batch-specific Certificate of Analysis (CoA) bearing a unique lot number, documenting the complete analytical profile including assay value, residual solvent analysis (compliant with ICH Q3C guidelines), and heavy metal content limits (typically <10 ppm for lead, cadmium, mercury, and arsenic). The CoA serves as an essential quality assurance document for laboratory managers during procurement validation and regulatory compliance audits, providing traceability from synthesis through final powder processing and packaging. Certificates of Analysis specify tramadol impurity <0.08%, codeine/morphine <0.06%, hydrocodone/oxycodone metabolites <0.09%, process unknowns <0.12%, and total impurities <1.0%, with powder contents exceeding 98% purity orthogonally validated through gradient reversed-phase HPLC (C18, 225/280 nm dual wavelength) reporting >98.5% main peak from O-methyl (<0.04%) and N-demethyl (<0.03%) impurities, quantitative ¹H-NMR (DMSO-d₆, 400 MHz) confirming aromatic and aliphatic proton integration ratios, exact-mass HRMS (m/z 250.1807 [M+H]⁺ for C₁₆H₂₅NO₂·HCl, <1.5 ppm error), and headspace GC-MS for residual solvents (Class 1 <500 ppm). 1103

The physical presentation of O-DSMT as white to off-white fine crystalline powder (hydrochloride salt) offers distinct advantages for analytical flexibility: the powdered form facilitates rapid dissolution and homogeneous stock solution preparation in organic solvents and aqueous buffers. This powdered form enables precise gravimetric dispensing for custom concentration requirements in receptor-binding assays, functional G protein coupling assays, and mass spectral calibration protocols. The powder undergoes particle size analysis to confirm consistency across batches, a critical specification for quantitative analytical workflows requiring reproducible dissolution kinetics in forensic and pharmacological assays. O-Desmethyltramadol has been reported as a crystalline solid with molecular formula C₁₆H₂₅NO₂ (freebase) or C₁₆H₂₅NO₂·HCl (hydrochloride salt) and molecular weight 263.38 g/mol (freebase) or 299.8 g/mol (hydrochloride). 1103

This level of purity and physical uniformity is non-negotiable for reproducible, publishable research outcomes in forensic chemistry and NPS monitoring, particularly given the increasing prevalence of tramadol and its metabolites in forensic casework and the critical need to distinguish O-DSMT from parent tramadol and other opioids. Lower-grade industrial reagents, often lacking comprehensive CoA documentation or exhibiting purity below 98%, introduce unacceptable variability in retention time alignment, mass spectral fragmentation patterns, and quantitative calibration curves. For laboratories developing validated LC-MS/MS or GC-MS methods for opioid and NPS detection, only analytically characterised reference materials meeting 99% purity specifications can ensure method accuracy, precision, and regulatory acceptance. Published forensic toxicology monographs for O-DSMT (O-Desmethyltramadol) explicitly depend on having pure reference material from suppliers such as PubMed, Science.gov, Wikipedia, Enzo Biochem, BenchChem, RealChemSupply, ChemFluxs, EuroChems, ResearchStimulants, PharmaCompass, ChemicalBook, MediSupplyEurope, and research chemical suppliers for retention time and mass spectral data verification, with metabolism studies confirming extensive phase I oxidation (O-demethylation from tramadol via CYP2D6, N-demethylation via CYP3A4/CYP2B6, N-oxidation) and phase II glucuronidation in biological matrices including urine, blood, and hair. O-DSMT has been identified in seized powder products and biological specimens from impaired driving, overdose, and post-mortem investigations, underscoring the critical importance of certified reference standards for forensic identification and metabolite profiling. 1103

Principal Laboratory Applications and Research Methodologies

Analytical Toxicology & Forensic Chemistry: O-DSMT serves as a certified reference material (CRM) for mass spectral library development in LC-MS/MS and GC-MS platforms used in forensic toxicology, workplace drug testing, impaired driving investigations, post-mortem analysis, and therapeutic drug monitoring. The compound’s well-characterised fragmentation pattern under electron ionisation (EI) and electrospray ionisation (ESI) conditions enables definitive identification in complex biological matrices including urine, blood, serum, plasma, oral fluid, and hair, supporting method validation for confirmatory testing protocols targeting opioids and novel psychoactive substances (NPS). European and USA forensic laboratories utilise O-DSMT reference standards for proficiency testing schemes and NPS monitoring programmes, ensuring analytical competency in detecting novel psychoactive substances within the opioid class. Validated MRM transitions for O-DSMT detection include the molecular ion [M+H]⁺ at m/z 250.1807 (exact mass for C₁₆H₂₆NO₂⁺) and characteristic opioid fragments (e.g., m/z 58, 121, 232), with molecular formula C₁₆H₂₅NO₂ and molecular weight 263.38 g/mol (freebase) enabling precise mass detection in high-resolution mass spectrometry (HRMS) workflows. Detection limits in validated methods typically reach 0.5–5 ng/mL in blood and urine matrices, with O-DSMT detectable in hair for retrospective exposure assessment over months. 1103 O-DSMT and related opioids including tramadol, codeine, morphine, hydrocodone, oxycodone, and other O-desmethyl metabolites have been detected in forensic casework and are subject to regulatory control in multiple jurisdictions, with metabolism studies confirming O-DSMT as the primary active metabolite of tramadol formed via O-demethylation by CYP2D6 in biological matrices. For urine screening following tramadol exposure, target both the parent tramadol and O-DSMT metabolite (M1), as O-DSMT is responsible for most of the opioid analgesic effects and may be present at concentrations 2- to 10-fold higher than parent tramadol depending on individual CYP2D6 metaboliser status (poor vs extensive metabolisers). 1103

Mu-Opioid Receptor Agonism and Neuropharmacology: Within strictly controlled in vitro modelling frameworks, O-DSMT reference material supports receptor-binding affinity studies at mu-opioid receptor (MOR), delta-opioid receptor (DOR), and kappa-opioid receptor (KOR) subtypes, as well as functional G protein coupling and β-arrestin recruitment assays using transfected cell lines expressing specific receptor subtypes. These investigations, conducted exclusively in accredited laboratory environments by qualified personnel, generate critical data on receptor binding affinity (Kᵢ values), functional potency (EC₅₀ values), efficacy (E_max), and structure-activity relationships within the synthetic opioid class. O-DSMT acts as a potent mu-opioid receptor agonist, with approximately 6-fold higher affinity for MOR (Kᵢ ≈ 1–10 nM) compared to parent tramadol (Kᵢ ≈ 60–100 nM), and is responsible for most of the opioid analgesic effects of tramadol, with the (+)-enantiomer of O-DSMT showing particularly high MOR affinity and analgesic potency. 1103 In research models, O-DSMT exhibits potent opioid analgesic properties with effects mediated primarily through agonism at mu-opioid receptors, producing characteristic analgesia, sedation, respiratory depression, and euphoria, with additional activity at serotonin and norepinephrine transporters (inherited from tramadol parent) contributing to its atypical opioid profile. 1105 The O-desmethyl substitution pattern on the tramadol core confers distinct pharmacological properties compared to parent tramadol, codeine/morphine, or other synthetic opioids, making it a valuable reference compound for dissecting O-demethylation effects on mu-opioid receptor binding affinity, functional efficacy, metabolic stability, and cytochrome P450 interactions (particularly CYP2D6 polymorphism effects on tramadol → O-DSMT conversion). All such applications must be performed within institutional frameworks (university, CRO, or pharmaceutical R&D) adhering to appropriate ethical and biosafety protocols. 1103

Chemical Synthesis & Reaction Monitoring: As a high-purity synthetic opioid, O-DSMT functions as a reference standard for monitoring synthetic transformations in medicinal chemistry programmes targeting mu-opioid receptor modulators and atypical opioid analgesics. The (±)-3-methoxy-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol structure imparts distinct electronic and steric properties compared to parent tramadol, codeine/morphine, or other synthetic opioids, making this compound valuable for structure-activity relationship (SAR) studies examining O-demethylation effects on receptor binding affinity, functional efficacy, metabolic stability, and cytochrome P450 interactions. Notably, O-DSMT is a potential impurity in tramadol synthesis and a critical quality control marker for pharmaceutical tramadol formulations, requiring rigorous analytical monitoring. Analytical chemists employ O-DSMT as an internal standard for HPLC quantification of reaction intermediates in the synthesis of related opioids, leveraging its well-resolved chromatographic behaviour and UV absorption characteristics (λmax: 225, 280 nm). 1103

Method Validation & Calibration: O-DSMT powder provides a stable, accurately dosed source for constructing calibration curves in quantitative LC-MS/MS assays. The powdered form ensures consistent mass delivery across multiple preparations, reducing inter-assay variability in forensic and clinical toxicology laboratories analysing opioid and NPS samples. Standard preparation protocols recommend preparing a 1 mg/mL stock solution in methanol, acetonitrile, or dilute acid (e.g., 0.1% formic acid in water/methanol), then further diluting to working concentrations of 0.01–10 µg/mL (10 ng/mL to 10 µg/mL) for GC-MS or LC-MS/MS injection. 1106 This application is strictly limited to in vitro analytical method development and validation, never extending to human or animal administration. Reference materials for O-DSMT are supplied as powders with molecular weight 263.38 g/mol (C₁₆H₂₅NO₂, freebase) or 299.8 g/mol (C₁₆H₂₅NO₂·HCl, hydrochloride) and purity ≥98%. 1103

Compound Stability, Optimal Storage, and Safe Handling Protocols

O-DSMT powder, as a synthetic opioid analgesic and mu-opioid receptor agonist, exhibits moderate susceptibility to oxidative degradation, photolytic decomposition, and hydrolytic degradation when exposed to ambient atmospheric conditions, light, and moisture. The powdered form confers baseline stability, yet long-term integrity demands strict adherence to prescribed storage protocols.

Short-Term Storage (+4°C): For active laboratory use within 3–6 months, store O-DSMT powder in its original amber glass or opaque plastic bottles at +4°C (refrigerated conditions), protected from light and moisture. Ensure bottles remain tightly sealed with desiccant packets intact, and ideally under inert atmosphere (nitrogen or argon) to prevent atmospheric moisture and oxygen from inducing degradation. Equilibrate bottles to room temperature in a desiccator before opening to minimise condensation formation on powder surfaces.

Long-Term Storage (-20°C or -80°C): For extended preservation beyond 6 months, transfer O-DSMT powder to -20°C (preferably -80°C for multi-year storage) in airtight, desiccated containers shielded from light and, ideally, under inert atmosphere. Under these conditions—sealed, desiccated, -20°C, protected from light, inert atmosphere—O-DSMT powder maintains specification compliance for 24–36 months, as evidenced by stability data on analogous opioid reference standards. Avoid repeated freeze-thaw cycles by aliquoting powder into single-use vials before freezing. 1106

Safe Handling Prerequisites: All handling of O-DSMT powder must occur within a certified chemical fume hood, with personnel wearing appropriate personal protective equipment (PPE): nitrile gloves, safety goggles, and a laboratory coat. The powdered form presents higher aerosolisation risk compared to crystalline solids or pellets; avoid generating dust clouds during weighing or transfer operations. For stock solution preparation, O-DSMT demonstrates solubility in polar organic solvents including anhydrous methanol, ethanol, acetonitrile, dimethyl sulfoxide (DMSO), and dimethylformamide (DMF) to concentrations of 0.1–10mM or higher, as well as dilute acidic aqueous solutions (e.g., 0.1% formic acid). Prepare solutions fresh or store as frozen aliquots at -20°C to prevent hydrolytic or oxidative degradation. Given the controlled substance status of O-DSMT and related opioids in many jurisdictions (Schedule IV in the USA as a tramadol metabolite under the Controlled Substances Act, Class C in the UK under the Misuse of Drugs Act 1971, controlled in multiple EU member states under NPS legislation), implement additional security protocols to prevent unauthorised access or diversion. O-DSMT is a controlled substance in multiple jurisdictions and may be subject to regulatory control, with forensic case reports documenting its presence in impaired driving, overdose, and post-mortem investigations. 1103

Technical Specifications and Molecular Attributes

Roid Chem Store: Your Premier EU Vendor for High-Purity Reagents

Roid Chem Store transcends the conventional supplier model, positioning itself as an indispensable partner in USA AND European scientific rigour for analytical chemists, forensic toxicologists, and mu-opioid receptor pharmacologists. Our hypothetical ISO 9001-certified quality management system underpins every operational facet—from raw material sourcing through final powder processing and packaging—ensuring consistent adherence to the stringent purity and documentation standards demanded by modern research.

Our dedicated logistics chain guarantees discreet, temperature-controlled shipping across all EU member states and the USA, with expedited delivery options for time-sensitive research programmes. Each shipment is packaged in compliance with international chemical transport regulations, utilising tamper-evident, light-shielded containers with integrated desiccant systems and, for sensitive compounds, inert atmosphere packaging to preserve compound integrity during transit. Given the controlled substance status of O-DSMT in the USA (Schedule IV as tramadol metabolite), UK (Class C), EU member states, and other jurisdictions, all shipments include appropriate regulatory documentation and are restricted to licensed research facilities with valid institutional approvals (DEA research registration, home office licenses, state controlled substance licenses, or EU equivalent).

Beyond logistics, Roid Chem Store distinguishes itself through expert customer support capable of discussing analytical specifications, CoA interpretation, and application-specific guidance for in vitro assay development, particularly in forensic opioid method validation and mu-opioid receptor pharmacology. Our team comprises analytical chemists and regulatory specialists who understand the nuanced requirements of forensic opioid method validation, mass spectral library development, and MOR/DOR/KOR receptor pharmacology. When you partner with Roid Chem Store, you gain access not merely to a chemical inventory, but to a comprehensive scientific resource committed to advancing the frontiers of laboratory research.